Report cover image

Global Central Nervous System (CNS) Stimulant Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 197 Pages
SKU # APRC20552971

Description

Summary

According to APO Research, The global Central Nervous System (CNS) Stimulant Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Central Nervous System (CNS) Stimulant Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Central Nervous System (CNS) Stimulant Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Central Nervous System (CNS) Stimulant Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Central Nervous System (CNS) Stimulant Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Central Nervous System (CNS) Stimulant Drugs include Takeda Pharmaceuticals, Sanofi, Thermo Fisher Scientific, Johnson and Johnson, Novartis, Merck, Roche, Eli Lilly and Company and Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Central Nervous System (CNS) Stimulant Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Central Nervous System (CNS) Stimulant Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Central Nervous System (CNS) Stimulant Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Central Nervous System (CNS) Stimulant Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Central Nervous System (CNS) Stimulant Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Central Nervous System (CNS) Stimulant Drugs sales, projected growth trends, production technology, application and end-user industry.

Central Nervous System (CNS) Stimulant Drugs Segment by Company

Takeda Pharmaceuticals
Sanofi
Thermo Fisher Scientific
Johnson and Johnson
Novartis
Merck
Roche
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Biogen
Shire
Perdue Pharma
Celltech
Astellas Pharma
Central Nervous System (CNS) Stimulant Drugs Segment by Type

Cocaine
Caffeine
Amphetamine
Others
Central Nervous System (CNS) Stimulant Drugs Segment by Application

Attention Deficit Hyperactivity Disorder (ADHD)
Narcolepsy
Others
Central Nervous System (CNS) Stimulant Drugs Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Stimulant Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Stimulant Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Stimulant Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Central Nervous System (CNS) Stimulant Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Central Nervous System (CNS) Stimulant Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Central Nervous System (CNS) Stimulant Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Central Nervous System (CNS) Stimulant Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Central Nervous System (CNS) Stimulant Drugs Market Size, 2020 VS 2024 VS 2031
1.3 Global Central Nervous System (CNS) Stimulant Drugs Market Size Estimates and Forecasts (2020-2031)
1.4 Global Central Nervous System (CNS) Stimulant Drugs Sales Estimates and Forecasts (2020-2031)
1.5 Global Central Nervous System (CNS) Stimulant Drugs Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Central Nervous System (CNS) Stimulant Drugs Market Dynamics
2.1 Central Nervous System (CNS) Stimulant Drugs Industry Trends
2.2 Central Nervous System (CNS) Stimulant Drugs Industry Drivers
2.3 Central Nervous System (CNS) Stimulant Drugs Industry Opportunities and Challenges
2.4 Central Nervous System (CNS) Stimulant Drugs Industry Restraints
3 Central Nervous System (CNS) Stimulant Drugs Market by Manufacturers
3.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Manufacturers (2020-2025)
3.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Manufacturers (2020-2025)
3.3 Global Central Nervous System (CNS) Stimulant Drugs Average Sales Price by Manufacturers (2020-2025)
3.4 Global Central Nervous System (CNS) Stimulant Drugs Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Central Nervous System (CNS) Stimulant Drugs Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Central Nervous System (CNS) Stimulant Drugs Manufacturers, Product Type & Application
3.7 Global Central Nervous System (CNS) Stimulant Drugs Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Central Nervous System (CNS) Stimulant Drugs Market CR5 and HHI
3.8.2 Global Top 5 and 10 Central Nervous System (CNS) Stimulant Drugs Players Market Share by Revenue in 2024
3.8.3 2024 Central Nervous System (CNS) Stimulant Drugs Tier 1, Tier 2, and Tier 3
4 Central Nervous System (CNS) Stimulant Drugs Market by Type
4.1 Central Nervous System (CNS) Stimulant Drugs Type Introduction
4.1.1 Cocaine
4.1.2 Caffeine
4.1.3 Amphetamine
4.1.4 Others
4.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type
4.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Type (2020-2031)
4.2.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Type (2020-2031)
4.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type
4.3.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Type (2020-2031)
4.3.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Type (2020-2031)
5 Central Nervous System (CNS) Stimulant Drugs Market by Application
5.1 Central Nervous System (CNS) Stimulant Drugs Application Introduction
5.1.1 Attention Deficit Hyperactivity Disorder (ADHD)
5.1.2 Narcolepsy
5.1.3 Others
5.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application
5.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Application (2020-2031)
5.2.3 Global Central Nervous System (CNS) Stimulant Drugs Sales Market Share by Application (2020-2031)
5.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application
5.3.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Application (2020-2031)
5.3.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Application (2020-2031)
6 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region
6.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2020-2031)
6.2.1 Global Central Nervous System (CNS) Stimulant Drugs Sales by Region (2020-2025)
6.2.2 Global Central Nervous System (CNS) Stimulant Drugs Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Central Nervous System (CNS) Stimulant Drugs Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Central Nervous System (CNS) Stimulant Drugs Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Central Nervous System (CNS) Stimulant Drugs Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region
7.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region
7.1.1 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2020-2025)
7.1.3 Global Central Nervous System (CNS) Stimulant Drugs Revenue by Region (2026-2031)
7.1.4 Global Central Nervous System (CNS) Stimulant Drugs Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Central Nervous System (CNS) Stimulant Drugs Revenue (2020-2031)
7.2.2 North America Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Central Nervous System (CNS) Stimulant Drugs Revenue (2020-2031)
7.3.2 Europe Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Revenue (2020-2031)
7.4.2 Asia-Pacific Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Central Nervous System (CNS) Stimulant Drugs Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Takeda Pharmaceuticals
8.1.1 Takeda Pharmaceuticals Comapny Information
8.1.2 Takeda Pharmaceuticals Business Overview
8.1.3 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Takeda Pharmaceuticals Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.1.5 Takeda Pharmaceuticals Recent Developments
8.2 Sanofi
8.2.1 Sanofi Comapny Information
8.2.2 Sanofi Business Overview
8.2.3 Sanofi Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Sanofi Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.2.5 Sanofi Recent Developments
8.3 Thermo Fisher Scientific
8.3.1 Thermo Fisher Scientific Comapny Information
8.3.2 Thermo Fisher Scientific Business Overview
8.3.3 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Thermo Fisher Scientific Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.3.5 Thermo Fisher Scientific Recent Developments
8.4 Johnson and Johnson
8.4.1 Johnson and Johnson Comapny Information
8.4.2 Johnson and Johnson Business Overview
8.4.3 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Johnson and Johnson Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.4.5 Johnson and Johnson Recent Developments
8.5 Novartis
8.5.1 Novartis Comapny Information
8.5.2 Novartis Business Overview
8.5.3 Novartis Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Novartis Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.5.5 Novartis Recent Developments
8.6 Merck
8.6.1 Merck Comapny Information
8.6.2 Merck Business Overview
8.6.3 Merck Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Merck Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.6.5 Merck Recent Developments
8.7 Roche
8.7.1 Roche Comapny Information
8.7.2 Roche Business Overview
8.7.3 Roche Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Roche Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.7.5 Roche Recent Developments
8.8 Eli Lilly and Company
8.8.1 Eli Lilly and Company Comapny Information
8.8.2 Eli Lilly and Company Business Overview
8.8.3 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Eli Lilly and Company Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.8.5 Eli Lilly and Company Recent Developments
8.9 Pfizer
8.9.1 Pfizer Comapny Information
8.9.2 Pfizer Business Overview
8.9.3 Pfizer Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Pfizer Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.9.5 Pfizer Recent Developments
8.10 GlaxoSmithKline
8.10.1 GlaxoSmithKline Comapny Information
8.10.2 GlaxoSmithKline Business Overview
8.10.3 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 GlaxoSmithKline Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.10.5 GlaxoSmithKline Recent Developments
8.11 Biogen
8.11.1 Biogen Comapny Information
8.11.2 Biogen Business Overview
8.11.3 Biogen Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Biogen Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.11.5 Biogen Recent Developments
8.12 Shire
8.12.1 Shire Comapny Information
8.12.2 Shire Business Overview
8.12.3 Shire Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 Shire Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.12.5 Shire Recent Developments
8.13 Perdue Pharma
8.13.1 Perdue Pharma Comapny Information
8.13.2 Perdue Pharma Business Overview
8.13.3 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Perdue Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.13.5 Perdue Pharma Recent Developments
8.14 Celltech
8.14.1 Celltech Comapny Information
8.14.2 Celltech Business Overview
8.14.3 Celltech Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 Celltech Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.14.5 Celltech Recent Developments
8.15 Astellas Pharma
8.15.1 Astellas Pharma Comapny Information
8.15.2 Astellas Pharma Business Overview
8.15.3 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
8.15.4 Astellas Pharma Central Nervous System (CNS) Stimulant Drugs Product Portfolio
8.15.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Central Nervous System (CNS) Stimulant Drugs Value Chain Analysis
9.1.1 Central Nervous System (CNS) Stimulant Drugs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Central Nervous System (CNS) Stimulant Drugs Production Mode & Process
9.2 Central Nervous System (CNS) Stimulant Drugs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Central Nervous System (CNS) Stimulant Drugs Distributors
9.2.3 Central Nervous System (CNS) Stimulant Drugs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.